908 Devices Strategic Shift: Desktop Sale To Repligen Optimizes Future Growth
Repligen acquired 908 Devices' MASS desktop portfolio for $70 million. This acquisition enhances Repligen's bioprocessing analytical technology offerings. 908 Devices saw a 31% revenue increase, supporting market demand. Desktop revenue growth indicates potential synergy with Repligen's existing portfolio. MASS stock rose 71.7% following the acquisition announcement.
View signal analysis